LAVAL,
QC, March 8, 2023 /PRNewswire/ -- Acasti
Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST and TSX-V:
ACST), a late-stage, specialty pharma company advancing three
clinical stage drug candidates addressing rare and orphan diseases,
today announced Jan D'alvise, CEO, will present and host one-on-one
meetings with investors at the Oppenheimer 33rd Annual Healthcare
Conference, held virtually and taking place on March 13-15, 2023.
The presentation will be available at 8:00am ET on Monday, March 13, 2023, and can be accessed here:
https://wsw.com/webcast/oppenheimer27/acst/2774359.
Acasti will also host virtual one-on-ones with investors on
March 13-15, 2023. To register for
the conference or request one-on-one meetings, please contact your
Oppenheimer representative or ACST@LythamPartners.com.
About Acasti
Acasti is a late-stage specialty pharma company with drug
delivery technologies and drug candidates addressing rare and
orphan diseases. Acasti's novel drug delivery technologies have the
potential to improve the performance of currently marketed drugs by
achieving faster onset of action, enhanced efficacy, reduced side
effects, and more convenient drug delivery—all which could help to
increase treatment compliance and improve patient outcomes.
Acasti's three lead clinical assets have each been granted Orphan
Drug Designation by the FDA, which provide the assets with seven
years of marketing exclusivity post-launch in the United States , and additional
intellectual property protection with over 40 granted and pending
patents. Acasti's lead clinical assets target underserved orphan
diseases: (i) GTX-104, an intravenous infusion targeting
Subarachnoid Hemorrhage (SAH), a rare and life threatening medical
emergency in which bleeding occurs over the surface of the brain in
the subarachnoid space between the brain and skull; (ii) GTX-102,
an oral mucosal spray targeting Ataxia-telangiectasia (A-T), a
progressive, neurodegenerative genetic disease that primarily
affects children, causing severe disability, and for which no
treatment currently exists; and (iii) GTX-101, a topical spray
targeting Postherpetic Neuralgia (PHN), a persistent and often
debilitating neuropathic pain caused by nerve damage from the
varicella zoster virus (shingles), which may persist for months and
even years.
For more information, please
visit: https://www.acastipharma.com/en.
Forward-Looking Statements
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking statements"
within the meaning of the U.S. Private Securities Litigation Reform
Act of 1995, as amended, Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended, and "forward-looking information" within the meaning of
Canadian securities laws (collectively, "forward-looking
statements"). Such forward looking statements involve known and
unknown risks, uncertainties, and other unknown factors that could
cause the actual results of Acasti to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are urged
to consider statements containing the terms "believes," "belief,"
"expects," "intends," "anticipates," "estimates", "potential,"
"should," "may," "will," "plans," "continue", "targeted" or other
similar expressions to be uncertain and forward-looking. Readers
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press
release.
These forward-looking statements are based upon Acasti's current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, including, without limitation: (i) the success and
timing of regulatory submissions of the planned Phase 3 safety
study for GTX-104 and Acasti's other pre-clinical and clinical
trials; (ii) regulatory requirements or developments and the
outcome of meetings with the FDA; (iii) changes to clinical trial
designs and regulatory pathways; (iv) legislative, regulatory,
political and economic developments; and (v) costs associated with
Acasti's clinical trials. The foregoing review of important factors
that could cause actual events to differ from expectations should
not be construed as exhaustive and should be read in conjunction
with statements that are included herein and elsewhere, including
the risk factors detailed in documents that have been and may be
filed by Acasti from time to time with the SEC. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Acasti undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were made.
Neither NASDAQ, the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this release.
For more information, please contact:
Acasti Contact:
Jan D'Alvise
Chief Executive Officer
Tel: 450-686-4555
Email:info@acastipharma.com
www.acastipharma.com
Investor Relations:
Robert
Blum
Lytham Partners, LLC
602-889-9700
ACST@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/acasti-pharma-to-participate-in-oppenheimer-33rd-annual-healthcare-conference-301765354.html
SOURCE Acasti Pharma Inc.